Official AMFI data
Arthkar — Understand Money, Invest Smartly
DSP

DSP Healthcare Fund

Sectoral / ThematicEquityVery High risk Rank 29 of 157

NAV · Direct-Growth

₹51.02+0.06+0.13%

As of 17 Aug 2026 · AMFI

NAV growth+15.5%
Aug ’25Aug ’26
Arthkar verdictSolid on the numbers

Returns

Beats category

1Y, 3Y, 5Y all ahead

Cost

Average

0.51% vs NaN% peers

Volatility

Below average

14.8% vs 16.3% cat (3Y)

Consistency

Steady

positive in 6 of 8 years

Beats its Sectoral / Thematic category on 1Y, 3Y & 5Y — and has been steadier than peers.

1Y return

+15.5%

+6.0 vs cat

3Y CAGR

+22.3%

+5.1 vs cat

5Y CAGR

+16.1%

+1.3 vs cat

AUM

₹3.3K Cr

fund size

Expense

0.51%

direct plan

Volatility 3Y

14.8%

▼ vs 16.3%

Go deeper on DSP Healthcare Fund

Two data-only views, computed from this fund's real NAV history — no projections.

In plain English

DSP Healthcare Fund is a Sectoral / Thematic scheme from DSP. The portfolio is ~94% in equities with 6% kept in cash and short-term debt. Long-run track record: about 16.1% CAGR over 5 years. Volatility is typical for equity — 20–30 % drawdowns happen during market stress. Worst historical drawdown: -22% in Mar 2020, recovered in 1 months. Wrong fit if you need this money in less than 7 years.

Auto-generated from holdings, returns and risk data. No paid placement, no copy-pasted boilerplate.

NAV history

Showing Direct · Growth · INF740KA1LG1

NAV (Direct-Growth)

₹51.0200

Last 1Y

+15.53%

Aug 25Min ₹39.92 · Max ₹51.14 · 238 ptsAug 26

Drawdown stories

The crashes you should know about — and how long the fund took to recover.

Mar 2020

-21.7%

Peak ₹12.69 on 20 Feb 2020 → trough ₹9.93 on 23 Mar 2020 (1 months down).

Recovered in 1 months· 20 Apr 2020

Jun 2022

-21.3%

Peak ₹25.24 on 15 Sept 2021 → trough ₹19.87 on 17 Jun 2022 (9 months down).

Recovered in 12 months· 21 Jun 2023

Apr 2025

-16.1%

Peak ₹45.95 on 7 Jan 2025 → trough ₹38.55 on 7 Apr 2025 (3 months down).

Recovered in 14 months· 4 Jun 2026

Computed from the full NAV history. We show drawdowns deeper than 10%, sorted by depth.

Honesty score

A 1–5 grade on the dimensions other sites won't surface — expense bloat, AUM bloat, concentration, mandate compliance.

4

Honesty score

4 / 5

Solid scheme on the dimensions we check. No red flags.

  • Expense ratio

    0.51% — well below typical 1% for equity.

  • AUM size

    ₹3.3K Cr.

  • Sector concentration

    Top 3 sectors = 97.7% — heavy concentration risk.

Computed from expense ratio, AUM, sector concentration and SEBI mandate compliance. No paid review.

Performance

Returns for various periods, with category average and peer rank.

PeriodReturnsCategory avgRank
1W-0.24%-0.40%99/ 286
1M+3.62%+2.47%95/ 286
3M+12.67%+8.01%43/ 286
6M+21.94%+6.33%12/ 278
YTD+17.20%+6.03%30/ 273
1Y+15.53%+9.52%63/ 258
2Y+11.28%+5.82%29/ 203
3Y+22.32%+17.18%29/ 157
5Y+16.09%+14.76%41/ 125
7Y+26.45%+18.88%4/ 104

Portfolio composition

Asset allocation

  • Equity93.65%
  • Cash6.35%

By market cap

  • Large cap20.84%
  • Mid cap13.51%
  • Small cap46.24%
  • Others19.41%

Concentration

Holdings

31

Avg market cap

₹51.3K Cr

Top 10 stocks

66.44%

Top 5 stocks

40.45%

Top 3 sectors

97.67%

Top holdings

Top 15 positions by weight, latest disclosure.

#InstrumentSectorWeight
  • 1

    Ipca Laboratories Ltd

    9.39%
  • 1

    Ipca Laboratories Ltd

    9.39%
  • 2

    Sun Pharmaceuticals Industries Ltd

    9.33%
  • 2

    Sun Pharmaceuticals Industries Ltd

    9.33%
  • 3

    Cipla Ltd

    7.68%
  • 3

    Cipla Ltd

    7.68%
  • 4

    Globus Medical Inc Class A

    7.58%
  • 4

    Globus Medical Inc Class A

    7.58%
  • 5

    Illumina Inc

    6.47%
  • 5

    Illumina Inc

    6.47%
  • 6

    Laurus Labs Ltd

    6.29%
  • 6

    Laurus Labs Ltd

    6.29%
  • 7

    Sai Life Sciences Ltd

    6.02%
  • 7

    Sai Life Sciences Ltd

    6.02%
  • 8

    Gland Pharma Ltd

    5.40%

Fundamentals (vs category)

Portfolio-weighted ratios, compared with the category average.

MetricFundCategory avgDiff
  • P/E ratio33.3241.09-7.77
  • P/B ratio4.555.83-1.28
  • Price / Sales4.575.71-1.14
  • Price / Cash Flow26.3530.54-4.19
  • Dividend yield0.54%0.63%-0.09
  • Return on equity (ROE)16.88%16.57%+0.31

Risk metrics

Standard deviation, Sharpe, Sortino, Beta — all vs category average.

Metric1Y3Y5YCat 1YCat 3YCat 5Y
  • Standard deviation

    Volatility — lower means steadier returns.

    12.9615.2815.1014.9216.2915.44
  • Sharpe ratio

    Risk-adjusted return — higher is better.

    0.471.040.700.480.980.58
  • Sortino ratio

    Like Sharpe but only counts downside volatility.

    0.771.931.180.831.710.94
  • Beta

    1 = moves with the market. <1 = less volatile.

    0.890.860.880.940.950.94

Peers in Sectoral / Thematic

Other schemes in the same SEBI category, ranked by AUM.

Available plans & options

PlanOptionFull nameISIN

Click a plan to see its NAV and chart above. Direct plans have lower expense ratios than Regular — same portfolio, more of the return stays with you.